Overview

Comparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility

Status:
Recruiting

Trial end date:
2023-03-01

Target enrollment:

Participant gender:

Summary

Several data emphasize the relation between tachycardia (>90/min) and high mortality during septic shock. The investigators previously demonstrated the high mortality associated with hypercontractility, tachycardia and the presence of a left ventricular obstruction. A severe hypovolemia, a hyper adrenergic stimulation or a severe vasoplegia can all explain this relation between tachycardia, hypercontractility and the mortality during septic shock. Landiolol is another short-term acting beta-blocker with a half-life of 4 minutes without any beta 2 activity or membrane stabilizing effect. The landiolol has been used in critically ill patients to control supraventricular tachycardia but not in this context of tachycardia and septic shock. The investigators hypothesize that landiolol by reducing the heart rate may improve the survival of patients treated for a septic shock and presenting with an hypercontractility state.

Phase:

N/A

Details

Lead Sponsor:

Centre Hospitalier Universitaire, Amiens

Collaborators:

Centre Hospitalier Arras
Centre Hospitalier de Beauvais
Centre Hospitalier de Bethune
Centre Hospitalier de Lens
Centre Hospitalier de Roubaix
Centre Hospitalier Universitaire de Nīmes
Centre Hospitalier VALENCIENNES
CH Beauvais
CH Calais
CH Cherbourg
CH Compiègne
CH Dieppe
CH Douai
CH Elbeuf
CH Laon
CH Le Havre
CH Lomme
CH Montreuil
Groupe Hospitalier Pitié-Salpêtrière
Henri Mondor University Hospital
Hôpital Edouard Herriot
Hospital Ambroise Paré Paris
Hospital Avicenne
Tourcoing Hospital
University Hospital, Brest
University Hospital, Caen
University Hospital, Lille
University Hospital, Montpellier

Treatments:

Landiolol